Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Gains from Investment Securities (2020 - 2024)

Historic Gains from Investment Securities for Bioventus (BVS) over the last 5 years, with Q4 2024 value amounting to $345000.0.

  • Bioventus' Gains from Investment Securities rose 1896.55% to $345000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $345000.0, marking a year-over-year decrease of 7478.07%. This contributed to the annual value of $1.4 million for FY2024, which is 9791.38% up from last year.
  • Bioventus' Gains from Investment Securities amounted to $345000.0 in Q4 2024, which was up 1896.55% from $483000.0 recorded in Q3 2024.
  • Bioventus' 5-year Gains from Investment Securities high stood at $3.4 million for Q2 2022, and its period low was -$463000.0 during Q4 2021.
  • For the 5-year period, Bioventus' Gains from Investment Securities averaged around $468400.0, with its median value being $290000.0 (2023).
  • Per our database at Business Quant, Bioventus' Gains from Investment Securities tumbled by 13525.18% in 2023 and then surged by 59285.71% in 2024.
  • Over the past 5 years, Bioventus' Gains from Investment Securities (Quarter) stood at $152000.0 in 2020, then plummeted by 404.61% to -$463000.0 in 2021, then skyrocketed by 160.04% to $278000.0 in 2022, then grew by 4.32% to $290000.0 in 2023, then rose by 18.97% to $345000.0 in 2024.
  • Its Gains from Investment Securities was $345000.0 in Q4 2024, compared to $483000.0 in Q3 2024 and $300000.0 in Q2 2024.